Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (DINOSAUR)
Sponsor: Alberta Children's Hospital
Listed as NCT03171818, this PHASE2 trial focuses on Neonatal Stroke and PAIS and remains ongoing. Sponsored by Alberta Children's Hospital, it has been updated 12 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Nov 2021 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alberta Children's Hospital
- The Hospital for Sick Children
- UMC Utrecht
For direct contact, visit the study record on ClinicalTrials.gov .